Functional impairments following stroke remain a significant therapeutic challenge. More than 60% of stroke patients do not regain full hand and arm mobility, highlighting a critical gap in recovery outcomes.

Mobia Medical, formerly MicroTransponder, is a medical device company that launched the Vivistim® Paired VNS™ System to stimulate the vagus nerve during rehabilitation therapy and daily activities to improve upper extremity motor function in chronic ischemic stroke patients with moderate-to-severe impairments. Vivistim, FDA-approved in 2021, results in 2-3x more improvements in arm and hand function compared with intensive rehabilitation alone.

With Vivistim, stroke programs can set a new standard of care by moving beyond traditional follow-up models to optimize outcomes and ensure access to advanced treatment options for stroke survivors and their families. Expanding follow-up beyond discharge and establishing a new standard of care within the stroke program aligns with current post-stroke rehabilitation guidelines and improves long-term outcomes.

Mobia offers a step-by-step plan for implementing a multidisciplinary Vivistim Program within healthcare systems along with Vivistim tools, training, and support resources to optimize program outcomes, including reimbursement support and prior authorization assistance as well as Clinical Navigators to assist with patient education and flow.

For neuroscience leaders committed to changing the standard of care for stroke survivors, learn more about Vivistim at vivistim.com/about/ or reach out to [email protected] or call 844-VIVISTIM to start implementing Vivistim into your stroke program today.